Letters
Funding of drug treatment of multiple sclerosis should not be delayed
BMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7116.1160b (Published 01 November 1997) Cite this as: BMJ 1997;315:1160
- D W Paty, Professor*a
- a Division of Neurology, University of British Columbia, Vancouver, Canada
- * D W Paty participated in the trial of Betaferon and is a consultant for Schering Health, which manufactures the drug.
Editor—I disagree with Hughes that it is appropriate to delay decisions on funding a treatment for multiple sclerosis.1 I can comment on the points that Hughes made in relation to the trial of interferon beta-lb.2 3 4
Firstly, the blinding in the trial was performed as efficiently as possible. We used two …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.